BIOMAT Database Logo BIOMAT Database Logo

Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding. 1990

U Andersson, and S A Eckernäs, and P Hartvig, and J Ulin, and B Långström, and J E Häggström
Psychiatric Research Center, University of Uppsala, Sweden.

Dopamine D2 receptor binding characteristics were studied by positron emission tomography (PET) using N-11C-methyl spiperone as receptor ligand in patients on longterm treatment with neuroleptic drugs and in control subjects. Eight of the patients had symptoms of tardive dyskinesia whereas three patients did not have any symptoms. Control subjects comprised 5 healthy volunteers and 7 patients with pituitary tumors. All patients had been free of neuroleptic drugs for at least 4 weeks. The time dependent regional radioactivity in the striatum was measured and the receptor binding rate, k3, proportional to receptor number, Bmax and association rate for the receptor was calculated in relation to the cerebellum. The lack in difference in k3 values between TD patients, neuroleptic treated patients without TD and control subjects throws doubt on the hypothesis that changes in striatal D2 dopamine receptor number or binding affinity is an etiological mechanism for persistent TD.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013134 Spiperone A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA. Spiroperidol,Spiroperone
D014055 Tomography, Emission-Computed Tomography using radioactive emissions from injected RADIONUCLIDES and computer ALGORITHMS to reconstruct an image. CAT Scan, Radionuclide,CT Scan, Radionuclide,Computerized Emission Tomography,Radionuclide Tomography, Computed,Scintigraphy, Computed Tomographic,Tomography, Radionuclide-Computed,Computed Tomographic Scintigraphy,Emission-Computed Tomography,Radionuclide Computer-Assisted Tomography,Radionuclide Computerized Tomography,Radionuclide-Computed Tomography,Radionuclide-Emission Computed Tomography,Tomography, Computerized Emission,CAT Scans, Radionuclide,CT Scans, Radionuclide,Computed Radionuclide Tomography,Computed Tomography, Radionuclide-Emission,Computer-Assisted Tomographies, Radionuclide,Computer-Assisted Tomography, Radionuclide,Computerized Tomography, Radionuclide,Emission Computed Tomography,Emission Tomography, Computerized,Radionuclide CAT Scan,Radionuclide CAT Scans,Radionuclide CT Scan,Radionuclide CT Scans,Radionuclide Computed Tomography,Radionuclide Computer Assisted Tomography,Radionuclide Computer-Assisted Tomographies,Radionuclide Emission Computed Tomography,Scan, Radionuclide CAT,Scan, Radionuclide CT,Scans, Radionuclide CAT,Scans, Radionuclide CT,Tomographic Scintigraphy, Computed,Tomographies, Radionuclide Computer-Assisted,Tomography, Computed Radionuclide,Tomography, Emission Computed,Tomography, Radionuclide Computed,Tomography, Radionuclide Computer-Assisted,Tomography, Radionuclide Computerized,Tomography, Radionuclide-Emission Computed
D017448 Receptors, Dopamine D2 A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES. Dopamine D2 Receptors,Dopamine-D2 Receptor,D2 Receptors, Dopamine,Dopamine D2 Receptor,Receptor, Dopamine-D2

Related Publications

U Andersson, and S A Eckernäs, and P Hartvig, and J Ulin, and B Långström, and J E Häggström
Striatal dopamine D2 binding correlates with locus of control: Preliminary evidence from [11C]raclopride Positron Emission Tomography.
December 2019, International journal of psychophysiology : official journal of the International Organization of Psychophysiology,
U Andersson, and S A Eckernäs, and P Hartvig, and J Ulin, and B Långström, and J E Häggström
Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.
February 1994, Archives of general psychiatry,
U Andersson, and S A Eckernäs, and P Hartvig, and J Ulin, and B Långström, and J E Häggström
Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography.
January 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,
U Andersson, and S A Eckernäs, and P Hartvig, and J Ulin, and B Långström, and J E Häggström
Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography.
August 1996, Psychopharmacology,
U Andersson, and S A Eckernäs, and P Hartvig, and J Ulin, and B Långström, and J E Häggström
Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography.
February 2000, The American journal of psychiatry,
U Andersson, and S A Eckernäs, and P Hartvig, and J Ulin, and B Långström, and J E Häggström
Positron-emission tomography in tardive dyskinesia.
January 1995, The Journal of neuropsychiatry and clinical neurosciences,
U Andersson, and S A Eckernäs, and P Hartvig, and J Ulin, and B Långström, and J E Häggström
In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography.
August 2012, Journal of psychopharmacology (Oxford, England),
U Andersson, and S A Eckernäs, and P Hartvig, and J Ulin, and B Långström, and J E Häggström
Positron emission tomography study of human narcolepsy: no increase in striatal dopamine D2 receptors.
September 1995, Neurology,
U Andersson, and S A Eckernäs, and P Hartvig, and J Ulin, and B Långström, and J E Häggström
No Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia Patients.
March 2011, Psychiatry investigation,
U Andersson, and S A Eckernäs, and P Hartvig, and J Ulin, and B Långström, and J E Häggström
Striatal dopamine D2 receptors in tardive dyskinesia: PET study.
November 1989, Journal of neurology, neurosurgery, and psychiatry,
Copied contents to your clipboard!